Table 2 Distribution of cytokines scores of the change from start of treatment to 16 weeks after the start of treatment by autoantibodies
From: Biologic predictors of clinical improvement in rituximab-treated refractory myositis
Change from baseline to 16 weeks later | Anti-synthetase | TIF | SRP | MJ | MI-2 | Other AutoAb | No AutoAb | Undefined | P value |
|---|---|---|---|---|---|---|---|---|---|
(N = 23) | (N = 15) | (N = 18) | (N = 15) | (N = 13) | (N = 18) | (N = 29) | (N = 9) | ||
IFNCKa | −6.7 | 7.0 | −0.3 | 1.2 | −6.1 | −0.7 | 2.0 | −8.7 | <.001 |
(−80.8, 15.5) | (−6.7, 35.3) | (−21.9, 28.8) | (−41.2, 23.6) | (−82.0, 31.6) | (−37.7, 18.4) | (−30.6, 15.9) | (−25.8, 10.5) | ||
TH1 | −3.4 | −0.9 | 0.4 | 0.8 | −2.6 | −3.6 | −0.3 | −2.4 | 0.039 |
(−44.9, 34.5) | (−4.9, 34.9) | (−44.0, 63.3) | (−20.7, 32.2) | (−27.8, 3.6) | (−20.7, 17.7) | (−59.8, 41.8) | (−6.0, 60.3) | ||
TH2 | −1.4 | 0.6 | 1.1 | 2.4 | 0.2 | −0.3 | 1.4 | 1.3 | 0.11 |
(−9.5, 6.1) | (−17.5, 5.8) | (−7.5, 41.1) | (−7.0, 41.4) | (−5.7, 8.8) | (−51.9, 19.5) | (−69.3, 25.5) | (−5.1, 23.8) | ||
TH17 | −0.0 | 3.3 | 3.9 | 0.0 | 2.1 | 0.6 | 3.0 | −1.0 | 0.50 |
(−22.4, 26.8) | (−20.2, 26.7) | (−15.8, 45.7) | (−25.3, 43.2) | (−18.8, 39.1) | (−22.0, 24.5) | (−20.4, 43.0) | (−13.3, 13.8) | ||
Innate | 2.0 | 3.7 | 2.7 | 3.6 | −1.0 | 1.4 | 7.6 | 2.1 | 0.029 |
(−21.7, 14.9) | (−7.8, 24.0) | (−6.6, 34.5) | (−20.3, 21.6) | (−24.3, 8.3) | (−14.5, 23.2) | (−16.5, 22.1) | (−20.1, 14.0) | ||
Regulatory | −5.8 | −1.9 | −0.7 | −0.2 | −3.4 | −7.2 | −1.4 | −2.9 | 0.028 |
(−50.3, 17.1) | (−15.4, 15.1) | (−15.4, 55.3) | (−16.6, 25.0) | (−32.2, 9.1) | (−50.0, 24.9) | (−47.0, 45.7) | (−11.7, 12.7) |